A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease

SUMMARY: The present multimodal treatment approach was designed to achieve prolonged tumor control in advanced gastric cancer. A total of 26 patients with stage IV gastric cancer (metastatic

disease _n_=25), ECOG performance status 0–3 and laparoscopically evaluated peritoneal status received a modified EAP schedule to prove chemosensitivity and to mobilize autologous

peripheral blood stem cells (aPBSC). Patients without progressive disease proceeded to tandem high-dose chemotherapy (HD-CT) and aPBSCT. Patients with >50% reduction of the target lesion

received a second cycle of HD-CT. Responders were selected for local R0 resections (D2 resection) according clinical criteria. Of 26 patients, 20(77%) achieved partial remission after

dose-intensive chemotherapy: local R0 resection was achieved in 12 out of 14 patients selected for surgery (46% of all patients). Eight of these R0-resected patients initially had peritoneal

carcinomatosis. With a median follow-up of 3.2 years, four patients are still alive. The median overall survival was 8.4 months (CI 2.5–14.4 months), for histologic regression grade 3

(seven out of 25 patients, 28%) 29 months (CI 12–46 months). The combined treatment approach is tolerable and feasible in advanced disease and opens a therapeutic window for a significant

proportion of patients, even in cases with histologically proven peritoneal carcinomatosis. Access through your institution Buy or subscribe This is a preview of subscription content, access

via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy

this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: *

Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS NEOADJUVANT SINTILIMAB IN COMBINATION WITH CONCURRENT

CHEMORADIOTHERAPY FOR LOCALLY ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: A SINGLE-ARM PHASE 2 TRIAL Article Open access 14 August 2023 A PHASE II RANDOMISED TRIAL OF

INDUCTION CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED PANCREATIC CANCER: THE TAIWAN COOPERATIVE ONCOLOGY GROUP T2212 STUDY Article 17 December 2021 NEOADJUVANT

CAMRELIZUMAB AND APATINIB COMBINED WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR LOCALLY ADVANCED GASTRIC CANCER: A MULTICENTER RANDOMIZED PHASE 2 TRIAL Article Open access 02 January 2024

REFERENCES * Hundahl SA, Phillips JL, Menck HR . The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American

Joint Committee on cancer staging, proximal disease, and the "different disease" hypothesis. _Cancer_ 2000; 88: 921–932. Article  CAS  Google Scholar  * Kelsen D, Atiq OT, Saltz L

_et al_. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. _J Clin Oncol_ 1992; 10: 541–548. Article  CAS  Google Scholar  * Webb A, Cunningham

D, Scarffe JH _et al_. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. _J Clin

Oncol_ 1997; 15: 261–267. Article  CAS  Google Scholar  * Vanhoefer U, Rougier P, Wilke H _et al_. Final results of a randomized phase III trial of sequential high-dose methotrexate,

fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for

Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. _J Clin Oncol_ 2000; 18: 2648–2657. Article  CAS  Google Scholar  * Ajani JA, Mansfield PF, Lynch PM _et

al_. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. _J Clin Oncol_ 1999; 17: 2403–2411. Article  CAS  Google Scholar  * Fink

U, Schuhmacher C, Stein HJ _et al_. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. _Br J Surg_ 1995; 82: 1248–1252.

Article  CAS  Google Scholar  * Wilke H, Stahl M, Fink U _et al_. Preoperative chemotherapy for unresectable gastric cancer. _World J Surg_ 1995; 19: 210–215. Article  CAS  Google Scholar 

* Plukker JT, Mulder NH, Sleijfer DT _et al_. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. _Br J Surg_

1991; 78: 955–958. Article  CAS  Google Scholar  * Melcher AA, Mort D, Maughan TS . Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in

gastro-oesophageal cancer. _Br J Cancer_ 1996; 74: 1651–1654. Article  CAS  Google Scholar  * Schuhmacher CP, Fink U, Becker K _et al_. Neoadjuvant therapy for patients with locally advanced

gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. _Cancer_ 2001; 91: 918–927. Article  CAS  Google Scholar  * Lowy AM, Feig BW,

Janjan N _et al_. A pilot study of preoperative chemo-radiotherapy for resectable gastric cancer. _Ann Surg Oncol_ 2001; 8: 519–524. Article  CAS  Google Scholar  * Yonemura Y, Kinoshita K,

Fujimura T _et al_. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. _Hepatogastroenterology_ 1996; 43: 1260–1272. CAS  PubMed

  Google Scholar  * Cascinu S, Ficarelli R, Safi MA _et al_. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. _Eur J Cancer_ 1997; 3: 1699–1702. Article  Google

Scholar  * Bokemeyer C, Lampe CS, Clemens MR _et al_. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer.

_Anticancer Drugs_ 1997; 8: 396–399. Article  CAS  Google Scholar  * Kollmannsberger C, Quietzsch D, Haag C _et al_. A phase II study of paclitaxel, weekly, 24-hour continous infusion

5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. _Br J Cancer_ 2000; 83: 458–462. Article  CAS  Google Scholar  * Shirao K, Shimada Y, Kondo H _et al_.

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. _J Clin Oncol_ 1997; 15: 921–927. Article  CAS  Google Scholar  * Berdel WE,

Heldmann T, Thiel E . Long-term results of a phase-II-pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract.

_Oncol Rep_ 2001;8: 341–342. CAS  PubMed  Google Scholar  * Roder JD, Bottcher K, Siewert JR _et al_. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study

1992. _Cancer_ 1993; 72: 2089–2097. Article  CAS  Google Scholar  * Lowy AM, Mansfield PF, Leach SD _et al_. Response to neoadjuvant chemotherapy best predicts survival after curative

resection of gastric cancer. _Ann Surg_ 1999; 229: 303–308. Article  CAS  Google Scholar  * Siewert JR, Bottcher K, Stein HJ _et al_. Relevant prognostic factors in gastric cancer: ten-year

results of the German Gastric Cancer Study. _Ann Surg_ 1998; 228: 449–461. Article  CAS  Google Scholar  * Wilke H, Preusser P, Fink U _et al_. Preoperative chemotherapy in locally advanced

and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. _J Clin Oncol_ 1989; 7: 1318–1326. Article  CAS  Google Scholar  * Kelly S, Harris KM, Berry E

_et al_. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. _Gut_ 2001; 49: 534–539. Article  CAS  Google Scholar  * Ozaki T, Flege S,

Kevric M _et al_. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. _J Clin Oncol_ 2003; 21: 334–341. Article  Google Scholar  * Burstein HJ, Harris LN,

Gelman R _et al_. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a

pilot study. _J Clin Oncol_ 2003; 21: 46–53. Article  CAS  Google Scholar  * Walsh GL, Taylor GD, Nesbitt JC, Amato RJ . Intensive chemotherapy and radical resections for primary

nonseminomatous mediastinal germ cell tumors. _Ann Thorac Surg_ 2000; 69: 337–343. Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department

of Hematology and Oncology, University of Regensburg, Germany A Reichle, H Wagner, M Zaiss & R Andreesen * Department of Surgery, University of Regensburg, Germany U Bolder & K-W

Jauch * Department of Gastroenterology, University of Regensburg, Germany H Messmann * Department of Pathology, University of Regensburg, Germany F Bataille, P Wild & F Hofstädter

Authors * A Reichle View author publications You can also search for this author inPubMed Google Scholar * U Bolder View author publications You can also search for this author inPubMed 

Google Scholar * F Bataille View author publications You can also search for this author inPubMed Google Scholar * H Messmann View author publications You can also search for this author

inPubMed Google Scholar * H Wagner View author publications You can also search for this author inPubMed Google Scholar * M Zaiss View author publications You can also search for this author

inPubMed Google Scholar * P Wild View author publications You can also search for this author inPubMed Google Scholar * F Hofstädter View author publications You can also search for this

author inPubMed Google Scholar * R Andreesen View author publications You can also search for this author inPubMed Google Scholar * K-W Jauch View author publications You can also search for

this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to A Reichle. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Reichle, A.,

Bolder, U., Bataille, F. _et al._ A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease. _Bone Marrow

Transplant_ 32, 665–671 (2003). https://doi.org/10.1038/sj.bmt.1704203 Download citation * Received: 26 November 2002 * Accepted: 13 March 2003 * Published: 16 September 2003 * Issue Date:

01 October 2003 * DOI: https://doi.org/10.1038/sj.bmt.1704203 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * advanced gastric cancer *

multimodal treatment * neoadjuvant chemotherapy